Rifaximin

Rifaximin Treatment for Irritable Bowel Syndrome

How well does rifaximin work in IBS patients who have had a positive LHBT? Alimentary Pharmacology & Therapeutics

Rifaximin helps clear refractory C. difficile infections

NEW YORK (Reuters Health) - Rifaximin (Xifaxan) can clear up refractory Clostridium difficile infections, a new study suggests.

Salix gains new rights as rifaximin deal with Alfa restructured

Salix Pharmaceuticals is again seeking new lines of revenue from its top-selling product, Xifaxan (rifaximin) for traveller's diarrhoea and hepatic encephalopathy, most recently by renegotiating with...

Salix and Alfa Wassermann expand rifaximin accord

USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive agreement by which Salix has licensed rights in the USA and Canada to an extended intestinal r...

XIFAXAN® 550mg (Rifaximin-A) Registered For Reduction Of Recurrence Of Episodes Of Overt Hepatic Encephalopathy In The EU

Alfa Wassermann and Norgine are pleased to announce that they have received European Marketing Authorisation for XIFAXAN(R) 550mg (rifaximin-alpha) / REFERO(R) / TARGAXAN(R) / TIXTELLER(R) in the redu...

Salix in deal for new rifaximin formulation

Alfa Wassermann S.p.A. (Bologna, Italy) granted Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) rights in the U.S. and Canada to develop and commercialize an extended intestinal release formulation of rifaxi...

TARGAXAN® 550 (Rifaximin-alpha 550 mg tablets) launched in the UK

Norgine Pharmaceuticals Limited and Alfa Wassermann are pleased to announce the launch of TARGAXAN® 550 in the UK...

DTB finds no overwhelming evidence for rifaximin

There is no overwhelming evidence of a benefit for rifaximin (Xifaxanta; Norgine) over existing standard treatments for travellers’...

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

BACKGROUND: Abnormal intestinal clearance is involved in the pathogenesis of small intestinal bacterial overgrowth (SIBO). It is known that partially hydrolysed guar gum affects intestinal motility. E...

Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac Disease.

BACKGROUND: Small intestinal bacterial overgrowth (SIBO) is one cause of a poor response to a gluten-free diet (GFD) and persistent symptoms in celiac disease. Rifaximin has been reported to improve s...

The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance.

AIM: Rifaximin is a non-absorbed antibiotic relative of rifampicin. The location of effect and staphylococcal resistance are two recent potential concerns with rifaximin. In this study we evaluate the...

The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome.

OBJECTIVES: Many studies have linked irritable bowel syndrome (IBS) with small intestinal bacterial overgrowth (SIBO), although they have done so on a qualitative basis using bre...

Rifaximin for Irritable Bowel Syndrome without Constipation.

To the Editor: Two issues are major drawbacks of the study by Pimentel et al. (Jan. 6 issue)(1) on rifaximin therapy for patients with irritable bowel syndrome (IBS) without constipation. First, the d...